PUBLIC COMPANY
saveIambic Therapeutics Inc
updated 3mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Flagship blends three biotech startups to form EtceleraEtiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability to better predict the way new medicines will fare in humans.biopharma_dive · 21d ago
- Biotech notches 31 IPOs already this year, with 4 more joining queueThe sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts…biospace · 28d ago
- Iambic CEO on taking an AI drug company publicFresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.biopharma_dive · 1mo ago
- City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipelineCity Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.biospace · 1mo ago
- Updated: Iambic rises after $150M IPO for AI-driven cancer pipelineNvidia-backed Iambic Therapeutics rose on its first day of trading after pricing its $150 million initial public offering Wednesday night. The cancer-focused biotech's stock {$IAM} gained about 13%…endpoints · 1mo ago
- Iambic goes public with $150M IPO to accelerate clinical development of oncology pipelineIambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development of its oncology pipeline.fiercebiotech · 1mo ago
- Iambic, an AI drug discovery specialist, banks $150M in an IPOPart of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”biopharma_dive · 1mo ago
- Parkinson’s cell therapy developer files to go publicAspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.biopharma_dive · 1mo ago
- TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering termsTRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push…biospace · 1mo ago
- Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listingEli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals brought in $116.7 million and $45 million from their respective IPOs, continuing a bumper year for biotech listings.fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that